Your browser doesn't support javascript.
loading
The novel STAT3 inhibitor WZ-2-033 causes regression of human triple-negative breast cancer and gastric cancer xenografts.
Zhong, Yan; Deng, Lin; Shi, Shuo; Huang, Qiu-Yao; Ou-Yang, Shu-Min; Mo, Jian-Shan; Zhu, Kai; Qu, Xin-Ming; Liu, Pei-Qing; Wang, Yuan-Xiang; Zhang, Xiao-Lei.
Affiliation
  • Zhong Y; National-Local Joint Engineering Laboratory of Druggability and New Drug Evaluation, Guangdong Engineering Laboratory of Druggability and New Drug Evaluation, Guangdong Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510006,
  • Deng L; National-Local Joint Engineering Laboratory of Druggability and New Drug Evaluation, Guangdong Engineering Laboratory of Druggability and New Drug Evaluation, Guangdong Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510006,
  • Shi S; National-Local Joint Engineering Laboratory of Druggability and New Drug Evaluation, Guangdong Engineering Laboratory of Druggability and New Drug Evaluation, Guangdong Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510006,
  • Huang QY; National-Local Joint Engineering Laboratory of Druggability and New Drug Evaluation, Guangdong Engineering Laboratory of Druggability and New Drug Evaluation, Guangdong Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510006,
  • Ou-Yang SM; National-Local Joint Engineering Laboratory of Druggability and New Drug Evaluation, Guangdong Engineering Laboratory of Druggability and New Drug Evaluation, Guangdong Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510006,
  • Mo JS; National-Local Joint Engineering Laboratory of Druggability and New Drug Evaluation, Guangdong Engineering Laboratory of Druggability and New Drug Evaluation, Guangdong Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510006,
  • Zhu K; Innovation Practice Center, Changchun University of Chinese Medicine, Changchun, 130117, China.
  • Qu XM; Innovation Practice Center, Changchun University of Chinese Medicine, Changchun, 130117, China.
  • Liu PQ; National-Local Joint Engineering Laboratory of Druggability and New Drug Evaluation, Guangdong Engineering Laboratory of Druggability and New Drug Evaluation, Guangdong Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510006,
  • Wang YX; National-Local Joint Engineering Laboratory of Druggability and New Drug Evaluation, Guangdong Engineering Laboratory of Druggability and New Drug Evaluation, Guangdong Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510006,
  • Zhang XL; National-Local Joint Engineering Laboratory of Druggability and New Drug Evaluation, Guangdong Engineering Laboratory of Druggability and New Drug Evaluation, Guangdong Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510006,
Acta Pharmacol Sin ; 43(4): 1013-1023, 2022 Apr.
Article in En | MEDLINE | ID: mdl-34267347
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Stomach Neoplasms / Triple Negative Breast Neoplasms Type of study: Etiology_studies / Prognostic_studies Limits: Animals / Humans Language: En Journal: Acta Pharmacol Sin Journal subject: FARMACOLOGIA Year: 2022 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Stomach Neoplasms / Triple Negative Breast Neoplasms Type of study: Etiology_studies / Prognostic_studies Limits: Animals / Humans Language: En Journal: Acta Pharmacol Sin Journal subject: FARMACOLOGIA Year: 2022 Type: Article